In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The role of macrophage migration inhibitory factor in prediction of adverse outcomes after st-segment elevation myocardial infarction

Session HFA Discoveries - ePosters

Speaker Associate Professor Irina Vishnevskaya

Event : HFA Discoveries 2020

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Diseases: Biomarkers
  • Session type : ePosters

Authors : I Vishnevskaya (Kharkiv,UA), MP Kopytsya (Kharkiv,UA), TYE Storozhenko (Kharkiv,UA), OV Petyunina (Kharkiv,UA), DP Babichev (Kharkiv,UA)

Authors:
I Vishnevskaya1 , MP Kopytsya1 , TYE Storozhenko1 , OV Petyunina1 , DP Babichev1 , 1L.T. Malaya Therapy national institution of NAMSU - Kharkiv - Ukraine ,

Citation:

The search of new markers that significantly predict adverse outcomes in patients with acute myocardial infarction (AMI) is still going. One of the promising biomarkers for the early adverse outcome prediction is proinflammatory cytokine macrophage migration inhibitory factor (MIF).

Purpose: to determine significance of MIF in prognosis of 6-months adverse outcomes after AMI.

Methods: The study involved 73 ST-segment elevation myocardial infarction (STEMI) patients (72.6% male and 27.4% female), average age was 58.25 ± 1.22 years. Control group of 12 healthy volunteers included. All patient involved to the study signed the informed consent. All patients underwent a baseline investigation which includes: standard electrocardiography, echocardiography, angiography, and determination of marker of myocardial necrosis – cardiac troponin T. In addition, the level of MIF determined during the first 12 hours after the STEMI, before the percutaneous coronary intervention. The endpoint was composite and included all-cause mortality, nonfatal myocardial infarction, nonfatal stroke and hospitalization for unstable angina, acute decompensated heart failure. During 6-months follow-up 18% patients reached the endpoint.

Results: the effect of several variables of clinical, instrumental and laboratory status were assessed on surviving patients. For identification of the main risk factors for adverse outcome, we have used logistic regression (LR) method. The level of MIF and number of injured coronary vessels constituted the most important risk factors for endpoint being reached; odds ratios in, respectively, were 1.0 and 2.76. Areas under the ROC for MIF-predicted 1-year outcome risk was 0.7; p=0.003; 95% Cl: 0.6 – 0.9. The level of biomarker more than 2583 pg/ml with 82% of sensitivity and 62% of specificity can predict 1-year composed outcome in patients after STEMI.

Conclusions. Biomarker MIF was independently associated with the risk of adverse outcomes and could be used in clinical practice to improve risk stratification of patients with STEMI.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are